Claim Missing Document
Check
Articles

Found 2 Documents
Search

Efficacy and Safety of Lenacapavir for HIV Pre-Exposure Prophylaxis (Prep): A Systematic Review Putu Ngurah Pradnya Wibawa; Ni Putu Lia Juliantini; Ni Luh Putu Serly Ekayanti
Jurnal Indonesia Sosial Sains Vol. 7 No. 5 (2026): Jurnal Indonesia Sosial Sains
Publisher : CV. Publikasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59141/jiss.v7i5.2316

Abstract

Lenacapavir, an antiretroviral agent, is a candidate for HIV prophylaxis, distinguished by its long-acting formulation, which facilitates biannual administration for preventive care. The objective of this investigation is to assess the efficacy and safety profile of Lenacapavir, drawing upon the findings of extant research. This scoping review analyzed articles published between march 2016 and march 2026 from PubMed, ScienceDirect, and OpenAlex. The inclusion criteria comprised English-language cohort studies, case-control studies, and cross-sectional studies examining the association between NAFLD and the risk of CKD. Fifteen articles were selected following a rigorous screening process. Lenacapavir is a highly effective HIV preventive drug that can reduce the risk of HIV transmission among various populations, including pregnant women, homosexual and heterosexual individuals, and others. The reported side effects are generally mild and not severe. Lenacapavir signifies a significant advancement in the realm of HIV prevention, especially for individuals at elevated risk who encounter challenges with consistent daily medication adherence. The effective global deployment of this intervention hinges on several critical factors: guaranteeing equitable accessibility, ensuring affordability within low- and middle-income nations, and upholding rigorous HIV testing protocols to mitigate the potential for viral resistance.
Comparative Effectiveness Of Ramipril Versus Losartan In Adults With Primary Hypertension: A Scoping Review Putu Ngurah Pradnya Wibawa; Ni Putu Lia Juliantini; Ni Luh Putu Serly Ekayanti
Indonesian Health Journal Vol. 5 No. 1 (2026): Indonesian Health Journal
Publisher : Riviera Publishing

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58344/ihj.v5i1.831

Abstract

Hypertension remains one of the leading global risk factors for cardiovascular morbidity and mortality. Despite the availability of multiple antihypertensive drug classes, achieving optimal blood pressure control continues to be a major clinical challenge worldwide. This research aims to compare the efficacy of Ramipril and Losartan in the management of Primary Hypertension. This scoping review analyzed articles published between January 2006 and January 2026 from PubMed, ScienceDirect, OpenAlex, and DOAJ. Inclusion criteria included English-language observational studies addressing the efficacy of both antihypertensives. Four articles were selected after a rigorous screening process. Ramipril was more effective in reducing SBP and DBP, whereas Losartan was superior for EF and LV remodeling. Ramipril also increased GSH and total antioxidant status, while Losartan was more effective for metabolic and vascular remodeling biomarkers. Ramipril is commonly associated with adverse effects such as cough, whereas dizziness is more frequently reported with Losartan. Losartan has been shown to be more effective in hypertensive patients with left ventricular hypertrophy (LVH) and may also contribute to improvements in insulin resistance. Further head-to-head comparison studies are needed to guide optimal therapy.